JP2017503820A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503820A5 JP2017503820A5 JP2016547570A JP2016547570A JP2017503820A5 JP 2017503820 A5 JP2017503820 A5 JP 2017503820A5 JP 2016547570 A JP2016547570 A JP 2016547570A JP 2016547570 A JP2016547570 A JP 2016547570A JP 2017503820 A5 JP2017503820 A5 JP 2017503820A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- administered
- composition according
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461929716P | 2014-01-21 | 2014-01-21 | |
| US61/929,716 | 2014-01-21 | ||
| US201461944361P | 2014-02-25 | 2014-02-25 | |
| US61/944,361 | 2014-02-25 | ||
| US201462021397P | 2014-07-07 | 2014-07-07 | |
| US62/021,397 | 2014-07-07 | ||
| PCT/US2015/012212 WO2015112578A1 (en) | 2014-01-21 | 2015-01-21 | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019166361A Division JP7164502B2 (ja) | 2014-01-21 | 2019-09-12 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503820A JP2017503820A (ja) | 2017-02-02 |
| JP2017503820A5 true JP2017503820A5 (enExample) | 2018-03-01 |
| JP6845012B2 JP6845012B2 (ja) | 2021-03-17 |
Family
ID=53681890
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547570A Active JP6845012B2 (ja) | 2014-01-21 | 2015-01-21 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2019166361A Active JP7164502B2 (ja) | 2014-01-21 | 2019-09-12 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2022168140A Pending JP2023015087A (ja) | 2014-01-21 | 2022-10-20 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2024151126A Pending JP2024170495A (ja) | 2014-01-21 | 2024-09-03 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019166361A Active JP7164502B2 (ja) | 2014-01-21 | 2019-09-12 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2022168140A Pending JP2023015087A (ja) | 2014-01-21 | 2022-10-20 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2024151126A Pending JP2024170495A (ja) | 2014-01-21 | 2024-09-03 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11084884B2 (enExample) |
| EP (3) | EP3096798B1 (enExample) |
| JP (4) | JP6845012B2 (enExample) |
| KR (4) | KR20240049627A (enExample) |
| CN (2) | CN106132442B (enExample) |
| AU (3) | AU2015209481C1 (enExample) |
| BR (1) | BR112016016916B1 (enExample) |
| CA (1) | CA2937329C (enExample) |
| DK (1) | DK3096798T3 (enExample) |
| EA (1) | EA038532B1 (enExample) |
| ES (2) | ES2856076T3 (enExample) |
| IL (3) | IL246864B (enExample) |
| MX (2) | MX387753B (enExample) |
| NZ (2) | NZ761006A (enExample) |
| PL (2) | PL3096798T3 (enExample) |
| PT (1) | PT3096798T (enExample) |
| WO (1) | WO2015112578A1 (enExample) |
| ZA (2) | ZA201605342B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2688093T3 (es) | 2010-01-06 | 2018-10-30 | Dyax Corp. | Proteínas de unión a calicreína plasmática |
| IL269565B2 (en) | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| WO2014113712A1 (en) | 2013-01-20 | 2014-07-24 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
| JP2016513682A (ja) | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
| PL3060908T3 (pl) | 2013-10-21 | 2021-10-25 | Takeda Pharmaceutical Company Limited | Diagnoza i leczenie chorób autoimmunologicznych |
| KR20250066486A (ko) | 2013-10-21 | 2025-05-13 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 |
| KR20240049627A (ko) * | 2014-01-21 | 2024-04-16 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도 |
| EP3122782A4 (en) | 2014-03-27 | 2017-09-13 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| IL254292B2 (en) * | 2015-03-30 | 2026-01-01 | Dyax Corp | Plasma kallikrein inhibitors and their uses for preventing the onset of hereditary angioedema |
| WO2017035263A1 (en) * | 2015-08-24 | 2017-03-02 | Biocryst Pharmaceuticals, Inc. | Compositions comprising a plasma kallikrein inhibitor |
| CA3002747A1 (en) * | 2015-10-19 | 2017-04-27 | Dyax Corp. | Immunoassay to detect cleaved high molecular weight kininogen |
| BR112018011622A2 (pt) * | 2015-12-11 | 2018-11-27 | Dyax Corp | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae |
| KR102513485B1 (ko) * | 2016-09-16 | 2023-03-23 | 다케다 파머수티컬 컴패니 리미티드 | 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커 |
| CN109716129B (zh) | 2016-09-16 | 2023-10-03 | 武田药品工业株式会社 | 用于遗传性血管性水肿的rna生物标记 |
| AU2018350992A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
| WO2019105435A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN118236391A (zh) | 2017-12-01 | 2024-06-25 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110997919B (zh) | 2017-12-01 | 2024-04-02 | 苏州瑞博生物技术股份有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| JP7261494B2 (ja) | 2017-12-01 | 2023-04-20 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN110959011B (zh) | 2017-12-29 | 2023-03-28 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
| EP3842534A4 (en) | 2018-08-21 | 2022-07-06 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE |
| EP3862024A4 (en) | 2018-09-30 | 2022-08-17 | Suzhou Ribo Life Science Co., Ltd. | SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE |
| CN112423794A (zh) | 2018-12-28 | 2021-02-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| US12163956B2 (en) | 2019-02-21 | 2024-12-10 | Takeda Pharmaceutical Company Limited | Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples |
| MX2021011110A (es) * | 2019-03-14 | 2022-01-19 | Takeda Pharmaceuticals Co | Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana. |
| JP7663951B2 (ja) | 2019-05-22 | 2025-04-17 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| AU2020280439B2 (en) | 2019-05-22 | 2025-08-14 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| CN113811613B (zh) | 2019-05-22 | 2024-04-05 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| WO2020238766A1 (zh) | 2019-05-24 | 2020-12-03 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| US20220315929A1 (en) * | 2019-05-24 | 2022-10-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof |
| CA3167336A1 (en) | 2020-01-13 | 2021-07-22 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| WO2021202948A2 (en) * | 2020-04-04 | 2021-10-07 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
| AU2023399037A1 (en) * | 2022-12-13 | 2025-06-05 | Astria Therapeutics, Inc. | Anti-plasma kallikrein antibody dosing regimens for treating plasma kallikrein associated disorders |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US5444156A (en) * | 1985-07-12 | 1995-08-22 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human plasma prekallikrein |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| WO1987005396A1 (en) | 1986-03-03 | 1987-09-11 | Brigham And Women's Hospital | A method for evaluating nephrotoxicity |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5045452A (en) | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| DE69533472T2 (de) | 1994-01-11 | 2006-01-12 | Dyax Corp., Cambridge | Kallikreinhemmende "kunitz-domäne"-proteine und derivaten davon |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| DE19632772A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
| US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| ES2392073T3 (es) | 2001-11-08 | 2012-12-04 | Abbott Biotherapeutics Corp. | Formulación farmacéutica líquida estable de anticuerpos IGG |
| DK2311432T3 (en) | 2002-06-07 | 2015-02-02 | Dyax Corp | Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| EP1674480A4 (en) | 2003-09-04 | 2007-06-20 | Riken | ANTIBODY RECOGNIZING THE REGIONAL SECTION CONTROLLING TGF-BETA ACTIVATION |
| WO2005075665A2 (en) | 2004-02-03 | 2005-08-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1) |
| JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| ES2601554T3 (es) | 2006-03-16 | 2017-02-15 | Dyax Corp. | Péptidos inhibidores de calicreína plasmática para uso en el tratamiento de trastornos oftálmicos |
| JP5322935B2 (ja) | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬 |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| KR100846354B1 (ko) | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | 혈청 당단백질부터 분리한 폐암 진단용 마커 |
| NZ582930A (en) * | 2007-07-20 | 2012-11-30 | Diamedica Inc | Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| CA2695012A1 (en) | 2007-08-23 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| EA019512B1 (ru) | 2008-07-02 | 2014-04-30 | Эмерджент Продакт Дивелопмент Сиэтл, Ллс | Il-6-опосредованная иммунотерапия |
| US8637454B2 (en) | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| CN101928346B (zh) | 2009-07-31 | 2013-01-16 | 华中科技大学同济医学院附属同济医院 | 一种抗人组织激肽释放酶单克隆抗体及其制备 |
| ES2688093T3 (es) | 2010-01-06 | 2018-10-30 | Dyax Corp. | Proteínas de unión a calicreína plasmática |
| IL269565B2 (en) * | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| TWI907924B (zh) | 2011-05-02 | 2025-12-11 | 日商武田藥品工業股份有限公司 | 抗-α4β7抗體之調配物 |
| ES2732243T3 (es) | 2012-02-16 | 2019-11-21 | Santarus Inc | Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A) |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| HUE044285T2 (hu) | 2013-01-20 | 2019-10-28 | Dyax Corp | PKal-mediálta rendellenességek értékelése, vizsgálata és kezelése |
| WO2014113712A1 (en) | 2013-01-20 | 2014-07-24 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
| JP2016513682A (ja) | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
| KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| KR20250066486A (ko) | 2013-10-21 | 2025-05-13 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 |
| KR20240049627A (ko) | 2014-01-21 | 2024-04-16 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도 |
| EP3122782A4 (en) | 2014-03-27 | 2017-09-13 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| IL254292B2 (en) | 2015-03-30 | 2026-01-01 | Dyax Corp | Plasma kallikrein inhibitors and their uses for preventing the onset of hereditary angioedema |
| BR112018011622A2 (pt) | 2015-12-11 | 2018-11-27 | Dyax Corp | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae |
| CA3037157A1 (en) * | 2016-09-16 | 2018-03-22 | Dyax Corp. | Metabolite biomarkers for diseases associated with the contact activation system |
| WO2019048961A1 (en) | 2017-09-05 | 2019-03-14 | Bat Call D. Adler Ltd. | DIAGNOSIS OF PATHOLOGIES USING INFRASONIC SIGNATURES |
| US20200109214A1 (en) | 2018-08-30 | 2020-04-09 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| MX2021011110A (es) | 2019-03-14 | 2022-01-19 | Takeda Pharmaceuticals Co | Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana. |
| CA3167336A1 (en) | 2020-01-13 | 2021-07-22 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
-
2015
- 2015-01-21 KR KR1020247010766A patent/KR20240049627A/ko active Pending
- 2015-01-21 NZ NZ761006A patent/NZ761006A/en unknown
- 2015-01-21 CN CN201580010172.XA patent/CN106132442B/zh active Active
- 2015-01-21 PL PL15740774T patent/PL3096798T3/pl unknown
- 2015-01-21 JP JP2016547570A patent/JP6845012B2/ja active Active
- 2015-01-21 EP EP15740774.3A patent/EP3096798B1/en active Active
- 2015-01-21 CA CA2937329A patent/CA2937329C/en active Active
- 2015-01-21 PT PT157407743T patent/PT3096798T/pt unknown
- 2015-01-21 DK DK15740774.3T patent/DK3096798T3/da active
- 2015-01-21 US US15/113,297 patent/US11084884B2/en active Active
- 2015-01-21 EP EP25221825.0A patent/EP4722720A2/en active Pending
- 2015-01-21 NZ NZ723369A patent/NZ723369A/en unknown
- 2015-01-21 EA EA201691470A patent/EA038532B1/ru unknown
- 2015-01-21 WO PCT/US2015/012212 patent/WO2015112578A1/en not_active Ceased
- 2015-01-21 ES ES15740774T patent/ES2856076T3/es active Active
- 2015-01-21 ES ES20209536T patent/ES3065185T3/es active Active
- 2015-01-21 PL PL20209536.0T patent/PL3848057T3/pl unknown
- 2015-01-21 KR KR1020227025028A patent/KR20220107077A/ko not_active Ceased
- 2015-01-21 CN CN202310760869.5A patent/CN116585468A/zh active Pending
- 2015-01-21 KR KR1020167022785A patent/KR102424183B1/ko active Active
- 2015-01-21 EP EP20209536.0A patent/EP3848057B1/en active Active
- 2015-01-21 KR KR1020247006911A patent/KR102903403B1/ko active Active
- 2015-01-21 AU AU2015209481A patent/AU2015209481C1/en active Active
- 2015-01-21 MX MX2016009428A patent/MX387753B/es unknown
- 2015-01-21 BR BR112016016916-6A patent/BR112016016916B1/pt active IP Right Grant
-
2016
- 2016-07-20 MX MX2021013665A patent/MX2021013665A/es unknown
- 2016-07-20 IL IL246864A patent/IL246864B/en active IP Right Grant
- 2016-08-02 ZA ZA201605342A patent/ZA201605342B/en unknown
-
2018
- 2018-12-12 IL IL263669A patent/IL263669B/en active IP Right Grant
-
2019
- 2019-09-12 JP JP2019166361A patent/JP7164502B2/ja active Active
-
2020
- 2020-07-28 ZA ZA2020/04653A patent/ZA202004653B/en unknown
- 2020-09-02 US US17/010,354 patent/US12384854B2/en active Active
- 2020-09-28 AU AU2020244370A patent/AU2020244370B2/en active Active
- 2020-10-14 IL IL278062A patent/IL278062B/en unknown
-
2022
- 2022-10-20 JP JP2022168140A patent/JP2023015087A/ja active Pending
-
2024
- 2024-05-23 AU AU2024203436A patent/AU2024203436A1/en active Pending
- 2024-09-03 JP JP2024151126A patent/JP2024170495A/ja active Pending
-
2025
- 2025-07-08 US US19/262,325 patent/US20260035482A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020002171A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| JP2017160208A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| FI3311834T3 (fi) | Alfa-4-beeta7-vasta-aineen formulaatio | |
| JP2018193377A5 (enExample) | ||
| JP2017507652A5 (enExample) | ||
| JP2017506626A5 (enExample) | ||
| JP2017501167A5 (enExample) | ||
| JP2019501886A5 (enExample) | ||
| JP2016529255A5 (enExample) | ||
| JP2018505882A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| JP2016528247A5 (enExample) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2017503014A5 (enExample) | ||
| JP2017513809A5 (enExample) | ||
| JP2011103891A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| JP2018514510A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| JP2013520996A5 (enExample) | ||
| JP2017160178A5 (enExample) | ||
| NZ723369A (en) | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |